Larimar Therapeutics' Stock Declines Amid Market Volatility Larimar Therapeutics' stock has dropped to a 52-week low of $2.21, reflecting broader market challenges. Despite this, the company remains focused on advancing its lead drug candidate, nomlabofusp, with plans for a Phase 3 trial and a Biologics License Application submission by late 2025.56